Corsair Pharma‘s experimental skin-worn patch designed to deliver treprostinil, an approved treatment for pulmonary arterial hypertension (PAH), appears to be working as intended, according to newly announced data from an early clinical trial in healthy volunteers. “These data support the potential of our transdermal [through-the-skin] platform as a…
Higher TAGLN2 gene activity may contribute to the development of pulmonary arterial hypertension (PAH), according to a new study. Using genetic analyses and experiments in animals, researchers identified two specific DNA sites that influenced TAGLN2 expression (activity) and PAH risk. These are two sites where a chemical mark called…
Discussion
I live with both idiopathic pulmonary hypertension (PH) and scleroderma, and earlier this month, I was taught a lesson in how quickly things can unravel when you’re with people who are well-versed in one condition while you’re dealing with symptoms of the other. I traveled to Washington, D.C., to…
Risk factors for pulmonary hypertension (PH) in people receiving maintenance hemodialysis, a blood-filtering treatment used when kidney function is severely reduced, appear to change with age, according to a single-center study in China. Diabetes was a risk factor for PH in patients 60 or older. In younger patients, PH…
Discussion
Discussion
Discussion
Discussion
Discussion
Discussion
Get regular updates to your inbox.
